WO2001038305A2 - Nouveaux antagonistes des recepteurs de l'il-8 - Google Patents
Nouveaux antagonistes des recepteurs de l'il-8 Download PDFInfo
- Publication number
- WO2001038305A2 WO2001038305A2 PCT/FR2000/003278 FR0003278W WO0138305A2 WO 2001038305 A2 WO2001038305 A2 WO 2001038305A2 FR 0003278 W FR0003278 W FR 0003278W WO 0138305 A2 WO0138305 A2 WO 0138305A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- formula
- indole
- acid
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to new compounds inhibiting the action of CXC chemokines such as IL-8, Gro, NAP-2, ENA-78 etc. on their receptors, their process of preparation, and their use for obtaining medicines.
- CXC chemokines such as IL-8, Gro, NAP-2, ENA-78 etc.
- LTL-8 (Interleukin-8) is a protein of 72 amino acids belonging to the superfamily of proteins capable of attracting leukocytes, also qualified as CXC or CC cytokines intercrine cytokines or more recently chemokines (Oppenheim et ai, Annu. Rev Immunol., 1991, 9, 617-648). Interleukin-8 has been given different names such as NAP-1 (neutrophil attractant / activation protein-1), NAF (neutrophil activating factor) and T-cell lymphocyte chemotactic factor. Many members of the chemokine family have been described to be involved in inflammatory processes and the migration of leukocytes.
- chemokines The family of chemokines is made up of two distinct sub-families: alpha- and beta-chemokines.
- Alpha-chemokines like IL-8, NAP-2 (Neutrophil activating peptide-2), MGSA / Gro, or Gro-alpha (melanoma growth stimulatory activity), and FENA-78, all have effects on attraction and activation of leukocytes and more particularly neutrophils.
- This subfamily also includes PF-4 (Platelet Factor-4), beta-thromboglobulin and CTAPIII, which have no effect on neutrophils.
- IL-8 was originally identified by its ability to attract and activate polymorphonuclear leukocytes (neutrophils). More recently, it has been shown that the expression of EL-8 is rapidly induced in different tissues or cells such as macrophages, fibroblasts, endothelial and epithelial cells and even neutrophils, in response to proinflammatory cytokines such as IL-1 alpha or beta or TNF alpha and other pro-inflammatory agents such as LPS (Van Damme J., Interleukin-8 and related chemotactic cytokines; 1994; the cytokines Handbook, 2nd Ed AW Thomson editor, Academic. Press, London, pp: 185-208).
- proinflammatory cytokines such as IL-1 alpha or beta or TNF alpha
- pro-inflammatory agents such as LPS (Van Damme J., Interleukin-8 and related chemotactic cytokines; 1994; the cytokines Handbook, 2nd Ed AW Thomson editor, Academic. Press, London, pp: 185-208
- Gro-alpha, Gro-beta, Gro-gamma and NAP-2 belong to the family of chemokines and, like 1TL-8, these proteins too have been called by different terms.
- the Gro-alpha, beta and gamma were respectively called MGSA (Melanoma Growth Stimulatory Activity) a, b and g (Richmond and Thomas, J. Cell Physiol., 1986, 129, 375-384; Cheng et al., J. Immunol., 1992, 148, 451-456). All these chemokines belong to the group of alpha-chemokines which have an ELR motif (Aspartate-Leucine-Arginate) upstream of the CXC motif characteristic of this subgroup. These chemokines all bind to the type 2 receptor or CXCR2.
- IL-8 receptors belonging to the family of receptors with seven trans-membrane domains coupled to G proteins have been characterized and cloned: the 1TL-8 type A receptor (IL-8RA) or CXCR1 which binds with a strong affinity FIL-8 and GCP-2, and the FIL-8 receptor type B (IL-8RB) or CXCR2 which has as specific ligands 1TL-8, GCP-2, Gro-alpha, Gro- beta, Gro-gamma and NAP-2 (Ponath, Exp. Opin. Invest. Drugs, 1998, 7, 1- 18). These two receptors have an amino acid sequence homology of 77%.
- IL-8RA 1TL-8 type A receptor
- CXCR1 which binds with a strong affinity FIL-8 and GCP-2
- IL-8RB FIL-8 receptor type B
- CXCR2 which has as specific ligands 1TL-8, GCP-2, Gro-alpha, Gro- beta, Gro-gamma and NAP-2
- IL-8 seems to be implicated in the phenomena of ischemia-reperfusion of the lung (Sekido et al, Nature, 1993, 365, 654-657).
- IL-8 seems to play a major role in alterations due to myocardial hypoxia / reperfusion (Kukielka et al., J. Clin. Invest., 1995, 95, 89-103).
- mice deficient in interleukin-8 receptors were generated by elimination of the gene coding for the murine receptor for FIL-8 homologous to the human type 2 receptor (CXCR2) (Cacalano et al, Science, 1994, 265 , 682-684).
- mice Although these mice are healthy, the characteristics of their neutrophils are modified. In fact, their ability to migrate into the peritoneum is reduced in response to an intraperitoneal injection of thioglycolate. All these results suggest that the chemokines of the 1TL-8 family are important mediators of the migration and activation of neutrophils and other cell types such as endothelial cells under certain inflammatory conditions. In addition, chemokines of the 1TL-8 family have been described as playing an important role in tumor growth, metastasis and tumor angiogenesis in many types of cancer (Hébert and Baker, Cancer Invest., 1993 , 11, 743-750; Richards et al, Am. J. Surg., 1997, 174. 507-512).
- the invention provides novel non-peptide compounds which have the property of binding to the CXCR2 receptor for 1TL-8 and other chemokines of the same family, by behaving as antagonists of these receptors.
- This property of the compounds according to the invention makes it possible to envisage their use as active principles of medicaments intended for the preventive or curative treatment of diseases in which the FEL-8 receptors and chemokines of the same family are involved, such as, for example. for example, rheumatoid arthritis, psoriasis or atypical dermatitis, diseases associated with pathological angiogenesis (such as cancer), proliferation of tumor cells and the formation of metastases (in the case of melanoma for example), asthma, chronic obstruction of the lungs, acute respiratory distress syndrome, inflammation of the colon, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxin shock.
- diseases in which the FEL-8 receptors and chemokines of the same family are involved such as, for example. for example, rheumatoid arthritis, psoriasis or atypical dermatitis, diseases associated with pathological angiogenesis (such as cancer), proliferation of tumor cells and the formation of metastases (in
- R 1 represents a halogen, a nitro group, a trifluoromethyl group or a C 1 -C 3 alkyl group
- R, R 3 and R each independently represent a hydrogen atom, a halogen, a C ⁇ -C 3 alkyl group, a nitro group, a trifluoromethyl group or a cyano group, or R? and R together form, with the aromatic nucleus to which they are attached, a condensed aromatic ring, and n is equal to 2 or 3.
- the invention also relates, as new products, to the esters and the addition salts with a mineral or organic base of the compounds of formula I.
- a compound of formula I or of its salts for the preparation of a medicament intended for the preventive or curative treatment of diseases dependent on an activation of the IL-8 receptors, such as for example , rheumatoid arthritis, acute respiratory distress syndrome, psoriasis, Crohn's disease, and more generally, any pathology related to massive infiltration of neutrophils.
- halogen includes fluorine, chlorine and bromine atoms, fluorine and chlorine being preferred.
- C 1 -C 3 alkyl group it is necessary to understand the methyl, ethyl, propyl, 1-methylethyl and cyclopropyl groups.
- R represents halogen, a nitro group, a trifluoromethyl group or a C1-C 3,
- R 2 and R 3 each independently represent a hydrogen atom, a halogen, a C 1 -C 3 alkyl group, or together form, with the phenyl ring to which they are attached, a condensed aromatic ring, and n is equal to 2 or 3, as well as their esters and addition salts with a mineral or organic base.
- Rj is a chlorine atom
- R 2 and / or R 3 each represent a chlorine atom or fluorine, or a methyl group, preferably in the meta and / or para position of the phenyl ring
- R is the hydrogen atom
- condensed aromatic ring is understood to mean a ring forming, with the aromatic nucleus supporting the substituents R, R 3 , R 4 , a group with 2 condensed aromatic rings such as for example a 2-naphthyl or 1-naphthyl group, the group 2 -naphthyle being preferred.
- the compounds of formula I which are acids, can be esterified with organic alcohols, in particular C 2 -C 3 aliphatic alcohols such as ethanol or isopropanol (or 1-methylethanol).
- organic alcohols in particular C 2 -C 3 aliphatic alcohols such as ethanol or isopropanol (or 1-methylethanol).
- esters ethyl esters are preferred.
- the compounds of formula I can be salified with a mineral or organic base.
- the term “mineral base” includes hydroxides of alkali metals such as sodium hydroxide, potassium hydroxide, lithine or alkaline earth metals such as lime.
- base organic means primary, secondary or tertiary amines, amino alcohols, certain non-toxic nitrogen heterocycles, as well as basic amino acids.
- the sodium or potassium salts are preferred, and the lysine, arginine or 2-amino-2-methyl-1,3-propanediol salts.
- the compounds of formula I can in particular be prepared by a process comprising the steps consisting in: a) reacting, according to a Friedel-Crafts type reaction, a cyclic diacid anhydride of formula:
- n 2 or 3
- R, R 3 and R4 each independently represent a hydrogen atom, a halogen, a C 1 -C 6 alkyl group or R 2 and R 3 form together with the aromatic nucleus to which they are attached a condensed aromatic ring, in an anhydrous solvent such as dichloromethane, in the presence of a Lewis acid such as for example aluminum chloride, at a temperature between -10 and + 50 ° C, to obtain a compound of formula:
- R 1 represents a halogen, a trifluoromethyl group, or a C 1 -C 3 alkyl group
- a solvent such as for example acetic acid
- the above-mentioned compounds of formula (V) can also be obtained directly by Friedel-Crafts type reaction between an acid chloride of formula:
- R represents a methyl group
- Rj represents a halogen, a trifluoromethyl group, a nitro group or a C ⁇ -C 3 alkyl group
- n represents 2 or 3, in particular by the action of N-bromosuccinimide, in a solvent such as carbon tetrachloride, to obtain the compound of formula:
- step b) consists in reacting the compound of formula VHI with a tin derivative having a nitro aromatic ring, such as for example trimethyl (4-nitrophenyl) tin, according to methods classics well known to those skilled in the art for forming the compounds of formula (I) in which R, R 3 or R 4 is a nitro group.
- a tin derivative having a nitro aromatic ring such as for example trimethyl (4-nitrophenyl) tin
- a suspension of 2.59 g (19.4.10 " mol) of aluminum chloride in 4 ml of dichloromethane is prepared.
- the mixture is cooled to -5 ° C. and a mixture of 0.97 ml (10.3.10 ") is gradually added mole) of fluorobenzene and 1.31 ml (8.4.10 "" mole) of the methyl ester of 6-chloro-6-oxohexanoic acid in 3 ml of dichloromethane keeping the temperature between - 4 and - 7 ° C.
- the temperature is then allowed to rise to 20 ° C. and, after 15 hours, it is hydrolyzed on acidified ice water.
- a mixture of 0.6 g of zinc chloride and 1.78 g of the compound obtained in stage a) above is prepared in 4.4 ml of acetic acid.
- This reaction medium is brought to 75-85 ° C for 3 hours and then cooled to room temperature (approx. 20 ° C).
- 20 ml of water are added and then 40 ml of ethyl acetate.
- the aqueous phase is separated and extracted again with 30 ml of ethyl acetate and the combined organic phases are washed with water, dried over magnesium sulfate and concentrated under reduced pressure.
- 1.74 g of oily product are thus obtained (ester of the expected acid) which is taken up in 10 ml of a 10% sodium hydroxide solution in ethanol.
- a mixture of 13.9 g (40.3.10 " mole) of the ester obtained according to preparation VU is prepared, 10.8 g (60.4.10 "" mole) of 4-chlorophenylhydrazine hydrochloride, 5.5 g (40, 3.10 " mole) of zinc chloride in 80 ml of acetic acid. This mixture is brought to 65-70 ° C and kept stirring at this temperature for 18 hours. After cooling, the reaction medium is filtered and the filtrate is hydrolyzed on cold water. The precipitated organic compound is extracted with 2 times 150 ml of ethyl acetate. The organic phase obtained is washed with water, dried over magnesium sulfate and concentrated under reduced pressure.
- a mixture of 500 mg (1.45.10 " mol) of the ester obtained according to preparation X is prepared in 10 ml of dioxane. 3 ml of a 3N sodium hydroxide solution are added and the reaction medium is brought to reflux for 2 hours The solvent is then removed under reduced pressure and the residue is taken up in 30 ml of water The solution obtained is acidified with N hydrochloric acid. The precipitate formed is extracted with 2 times 50 ml of acetate.
- the expected acid is obtained in the form of a brown solid with a yield of 93%.
- the expected product is obtained in the form of an orange paste with a yield of 65%.
- a mixture of 480 mg (1.18 ⁇ 10 3 mole) of the ester obtained according to preparation XX is prepared, 870 mg (9.7 ⁇ 10 ⁇ 4 "1 mole) of cuprous cyanide and 2 ml of N-methyl-2-pyrrolidone which heated at reflux for 3 hours.
- the reaction medium is then cooled and 10 ml of water are added.
- the mixture is stirred at room temperature for 15 minutes and then 8 ml of ethylenediamine are added.
- the mixture is then extracted three times with toluene and the combined organic phases are dried and concentrated under reduced pressure.
- a solution of 0.4 g (1.21 ⁇ 10 ⁇ 3 mol) of the compound obtained according to preparation XXIV and of 0.32 g (1.83 ⁇ 10 ° mol) of 4-chloro-3-fluorophenylboronic acid in 14 ml is prepared. ethanol and 14 ml of toluene. 0.16 g (3.75.10 "3 mole) of lithium chloride, 70 mg (6.10 ° mole) of tetrakis (triphenylphosphine) palladium and 3 ml (3.10 ") are then added with stirring. 3 mol) of a 1M solution of sodium carbonate.
- 5-chloro-1H-indole-3-propanoic acid, methyl ester A solution of 232 mg (1.04 ⁇ 10 3 mole) of 5-chloro-1H-indole-3-propanoic acid is prepared in 14 ml of ethanol and we add, at room temperature,
- 3,5-Dimethyl-4-fluorophenylboronic acid is obtained, with a yield of 22%, according to a process analogous to the preparation of phenylboronic derivatives. by successive action of n-BuLi. then isopropyl borate on 5-bromo-2-fluoro- 1, 3-dimethylbenzene
- R and R, form a 2-naphthyl group with phenyl : "sodium salt of 1 example Biological activity
- the human IL-8 labeled with iodine 125 was obtained from NEN (Les Ulis) and has a specific activity of 2200 Ci / mmol.
- the recombinant human CXCR2 receptor was expressed in HEK 293 (ATCC. CRL-1573) K-562 (ATCC. CCL-243) or THP-1 (ATCC, TIB-202) cells.
- the HEK 293 cells are maintained in culture in DMEM medium (GIBCO) containing 4.5 g / 1 of glucose. 10% fetal calf serum, 1% Glutamax. 1% nonessential amino acids.
- K-562 and THP-1 cells are kept in culture in RPMI1640 medium (GIBCO) containing 10% fetal calf serum. 1% nonessential amino acids. 1 mM sodium pyruvate, 100 IU / ml of penicillin and 100 ⁇ g / ml of streptomycin. The cells are used when the cultures have reached 80% confluence.
- the membranes are prepared according to the protocol previously described (Bastian et al, Br. J. Pharmacol. 1997, 122, 393-399) except the homogenization buffer was replaced by a buffered saline solution at pH 8.0 containing 20 mM Tris . 1.2 mM MgS0 4 . 0.1 mM EDTA and 25 mM NaCl.
- the competition experiments are carried out in 96-well plates of 1 ml. at room temperature, in a final volume of 0.25 ml.
- the affinities of the compounds described in the present invention were also determined by a whole cell binding test.
- the transfected THP-1 or K-562 cells are suspended in the binding test buffer (PBS without calcium or magnesium containing 0.5% BSA (weight / volume), pH 7.4) at a rate of 2, 5 x 10 6 cells / ml.
- Competition experiments are carried out in 1-well 96-well plates in a final volume of 0.25 ml.
- 0.5 x 10 ° cells are incubated with decreasing concentrations of the test compound (100 ⁇ M at 0.01 nM) and 150 ⁇ M of [ I2: T] - ⁇ L-8.
- Non-specific binding is determined in the presence of 300 nM of non-radiolabelled chemokine.
- the reaction is stopped by rapid filtration under vacuum on a Whatman GF / C filter previously incubated for 1 h in a 3% polyethylene glycol solution (weight / volume).
- the filters are washed with a PBS solution at pH 7.4 containing 0.5 M NaCl.
- the radioactivity contained in the filters is measured in a gamma counter.
- the compounds of formula I described in the present invention tested at a concentration of 10 ⁇ M inhibit at least 95% the binding of [ 125 I] -IL-8 on the CXCR2 receptor.
- THP-1 cells expressing the recombinant CXCR2 receptors U937 cells differentiated with DMSO (Dimethyl sulfoxide) at 1% (v / v) or Eol3 cells are incubated in the presence of a fluorescent indicator Fura-2 AM at a concentration of 5 ⁇ M for 1 h at 37 ° C.
- DMSO Dimethyl sulfoxide
- the cells are washed and suspended at the concentration of 1 ⁇ 10 6 cells / ml in a saline solution containing: 136 mM NaCl, 4.7 nM KC1, 1.2 mM MgSO 4 , 1 , 6 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 11 mM glucose, 5 mM HEPES, pH 7.4.
- the cell suspension (2 ml) was placed in a quartz cuvette and the fluorescence intensity at 510 nm was measured on a spectrofluorimeter type LS50B (Perkin-Elmer) after excitations alternately at 340 nm and 380 nm.
- the ratio of fluorescence intensities after excitation at 340 nm and 380 nm is determined and the intracellular calcium concentration is calculated according to the formula:
- K d represents the affinity constant of the Fura-2 and calcium complex
- Rmax is the maximum fluorescence intensity determined after addition of 1 ⁇ M of the Bromo-A23187 ionophore
- Rmin is the minimum ratio determined after addition of 10 mM of EGTA consecutive to the addition of ionophore
- Sf2 / Sb2 is the ratio of the fluorescence values under excitation at 380 nm determined at Rmin and Rmax, respectively.
- the compounds of formula I described in the present invention inhibit the release of calcium induced by 1TL-8 or Gro-alpha.
- the use of the compounds of formula I is recommended as active principles of medicaments intended for a preventive or curative treatment in mammals, in particular in humans, with regard to diseases related to set of IL-8 and / or chemokines of the same family, and which are generally characterized by a massive invasion of neutrophils.
- rheumatoid arthritis psoriasis or atypical dermatitis
- diseases associated with pathological angiogenesis such as cancer
- proliferation of tumor cells and the formation of metastases (in the case of melanoma for example)
- asthma chronic obstruction of the lungs
- acute respiratory distress syndrome colon inflammation
- Crohn's disease ulcerative colitis.
- the compounds of formula I must be administered in an amount sufficient to antagonize 1TL-8 by binding competitively to the receptors.
- the dose of active ingredient depends on the method of administration and the type of pathology and is generally between 0.01 and 10 mg / kg.
- the compounds of formula I can also be combined with another active ingredient. In the context of their therapeutic use, the compounds of formula I will generally be administered in various forms, in combination with the excipients commonly used.
- the formulation used may be an oral form, such as for example capsules, tablets containing the solid active ingredient in a sprayed or micronized form, a syrup or a solution containing the active ingredient in solution, suspension, emulsion or microemulsion .
- the formulation can also be presented in a form which can be administered for topical use, for example a cream or a lotion or a transdermal device such as an adhesive patch.
- the active principle can also be formulated for a mode of administration by subcutaneous, intramuscular or intravenous injection.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020027006183A KR20020050280A (ko) | 1999-11-25 | 2000-11-24 | 신규 아이엘-8 수용체 안타고니스트 |
PL00355724A PL355724A1 (en) | 1999-11-25 | 2000-11-24 | Novel il-8 receptor antagonists |
CA002392225A CA2392225A1 (fr) | 1999-11-25 | 2000-11-24 | Nouveaux antagonistes des recepteurs de l'il-8 |
JP2001539861A JP2003514894A (ja) | 1999-11-25 | 2000-11-24 | 新規il−8受容体アンタゴニスト |
EP00985320A EP1232144B1 (fr) | 1999-11-25 | 2000-11-24 | Antagonistes des recepteurs de l'il-8 |
SK689-2002A SK6892002A3 (en) | 1999-11-25 | 2000-11-24 | Novel il-8 receptor antagonists |
BR0015695-7A BR0015695A (pt) | 1999-11-25 | 2000-11-24 | Novos antagonistas dos receptores de il-8 |
DE60009544T DE60009544T2 (de) | 1999-11-25 | 2000-11-24 | IL-8-Rezeptorantagonisten |
MXPA02005232A MXPA02005232A (es) | 1999-11-25 | 2000-11-24 | Antagonistas novedosos de los receptores de il-8. |
HU0203603A HUP0203603A3 (en) | 1999-11-25 | 2000-11-24 | Novel il-8 receptor antagonist indole derivatives and pharmaceutical compositions containing them |
IL14983800A IL149838A0 (en) | 1999-11-25 | 2000-11-24 | Novel il-8 receptor antagonists |
US10/130,454 US6605633B1 (en) | 1999-11-25 | 2000-11-24 | IL-8 receptor antagonists |
AT00985320T ATE263150T1 (de) | 1999-11-25 | 2000-11-24 | Il-8 rezeptor antagonisten |
AU21776/01A AU2177601A (en) | 1999-11-25 | 2000-11-24 | Novel il-8 receptor antagonists |
NZ519126A NZ519126A (en) | 1999-11-25 | 2000-11-24 | Novel IL-8 receptor antagonists |
NO20022460A NO20022460L (no) | 1999-11-25 | 2002-05-24 | Nye IL-8-reseptorantagonister |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/14837 | 1999-11-25 | ||
FR9914837A FR2801585B1 (fr) | 1999-11-25 | 1999-11-25 | Nouveaux antagonistes des recepteurs de l'ii-8 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001038305A2 true WO2001038305A2 (fr) | 2001-05-31 |
WO2001038305A3 WO2001038305A3 (fr) | 2002-01-24 |
Family
ID=9552533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/003278 WO2001038305A2 (fr) | 1999-11-25 | 2000-11-24 | Nouveaux antagonistes des recepteurs de l'il-8 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6605633B1 (fr) |
EP (1) | EP1232144B1 (fr) |
JP (1) | JP2003514894A (fr) |
KR (1) | KR20020050280A (fr) |
CN (1) | CN1391556A (fr) |
AT (1) | ATE263150T1 (fr) |
AU (1) | AU2177601A (fr) |
BR (1) | BR0015695A (fr) |
CA (1) | CA2392225A1 (fr) |
CZ (1) | CZ20021810A3 (fr) |
DE (1) | DE60009544T2 (fr) |
ES (1) | ES2218266T3 (fr) |
FR (1) | FR2801585B1 (fr) |
HU (1) | HUP0203603A3 (fr) |
IL (1) | IL149838A0 (fr) |
MX (1) | MXPA02005232A (fr) |
NO (1) | NO20022460L (fr) |
NZ (1) | NZ519126A (fr) |
PL (1) | PL355724A1 (fr) |
RU (1) | RU2002113771A (fr) |
SK (1) | SK6892002A3 (fr) |
WO (1) | WO2001038305A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092568A1 (fr) * | 2001-05-17 | 2002-11-21 | Laboratoires Fournier Sa | Derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
WO2003104180A1 (fr) * | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Procede de preparation d'acide 4-(4-fluorobenzoyl) butyrique |
EP1648867A1 (fr) * | 2003-07-17 | 2006-04-26 | Plexxikon, Inc. | Composes ayant une activite sur des ppar |
US7531568B2 (en) | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
US7572806B2 (en) | 2003-07-17 | 2009-08-11 | Plexxikon, Inc. | PPAR active compounds |
US8053463B2 (en) | 2007-03-08 | 2011-11-08 | Plexxikon Inc. | PPAR active compounds |
WO2021252849A1 (fr) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'apol1 et leur utilisation |
US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
US11801234B2 (en) | 2020-03-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis |
US11866446B2 (en) | 2020-08-26 | 2024-01-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018393A1 (fr) * | 1994-12-13 | 1996-06-20 | Smithkline Beecham Corporation | Nouveaux composes |
WO2000051984A1 (fr) * | 1999-03-04 | 2000-09-08 | Merck Sharp & Dohme Limited | Derives de 2-aryle indole utilises comme antagonistes des tachykinines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1000017A4 (fr) | 1997-07-29 | 2000-10-18 | Smithkline Beecham Corp | Antagonistes du recepteur il-8 |
-
1999
- 1999-11-25 FR FR9914837A patent/FR2801585B1/fr not_active Expired - Fee Related
-
2000
- 2000-11-24 US US10/130,454 patent/US6605633B1/en not_active Expired - Fee Related
- 2000-11-24 CN CN00816057A patent/CN1391556A/zh active Pending
- 2000-11-24 AU AU21776/01A patent/AU2177601A/en not_active Abandoned
- 2000-11-24 EP EP00985320A patent/EP1232144B1/fr not_active Expired - Lifetime
- 2000-11-24 IL IL14983800A patent/IL149838A0/xx unknown
- 2000-11-24 DE DE60009544T patent/DE60009544T2/de not_active Expired - Fee Related
- 2000-11-24 HU HU0203603A patent/HUP0203603A3/hu unknown
- 2000-11-24 BR BR0015695-7A patent/BR0015695A/pt not_active Application Discontinuation
- 2000-11-24 ES ES00985320T patent/ES2218266T3/es not_active Expired - Lifetime
- 2000-11-24 JP JP2001539861A patent/JP2003514894A/ja active Pending
- 2000-11-24 CZ CZ20021810A patent/CZ20021810A3/cs unknown
- 2000-11-24 MX MXPA02005232A patent/MXPA02005232A/es not_active Application Discontinuation
- 2000-11-24 CA CA002392225A patent/CA2392225A1/fr not_active Abandoned
- 2000-11-24 PL PL00355724A patent/PL355724A1/xx not_active Application Discontinuation
- 2000-11-24 WO PCT/FR2000/003278 patent/WO2001038305A2/fr not_active Application Discontinuation
- 2000-11-24 SK SK689-2002A patent/SK6892002A3/sk unknown
- 2000-11-24 RU RU2002113771/04A patent/RU2002113771A/ru unknown
- 2000-11-24 NZ NZ519126A patent/NZ519126A/xx unknown
- 2000-11-24 KR KR1020027006183A patent/KR20020050280A/ko not_active Application Discontinuation
- 2000-11-24 AT AT00985320T patent/ATE263150T1/de not_active IP Right Cessation
-
2002
- 2002-05-24 NO NO20022460A patent/NO20022460L/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996018393A1 (fr) * | 1994-12-13 | 1996-06-20 | Smithkline Beecham Corporation | Nouveaux composes |
WO2000051984A1 (fr) * | 1999-03-04 | 2000-09-08 | Merck Sharp & Dohme Limited | Derives de 2-aryle indole utilises comme antagonistes des tachykinines |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092568A1 (fr) * | 2001-05-17 | 2002-11-21 | Laboratoires Fournier Sa | Derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
FR2824826A1 (fr) * | 2001-05-17 | 2002-11-22 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
WO2003104180A1 (fr) * | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Procede de preparation d'acide 4-(4-fluorobenzoyl) butyrique |
US7572806B2 (en) | 2003-07-17 | 2009-08-11 | Plexxikon, Inc. | PPAR active compounds |
US8367828B2 (en) | 2003-07-17 | 2013-02-05 | Plexxikon Inc. | PPAR active compounds |
US7476746B2 (en) | 2003-07-17 | 2009-01-13 | Plexxikon, Inc. | PPAR active compounds |
US7491831B2 (en) | 2003-07-17 | 2009-02-17 | Plexxikon, Inc. | PPAR active compounds |
EP1648867A1 (fr) * | 2003-07-17 | 2006-04-26 | Plexxikon, Inc. | Composes ayant une activite sur des ppar |
US7723374B2 (en) | 2003-07-17 | 2010-05-25 | Plexxikon, Inc. | PPAR active compounds |
EP1648867A4 (fr) * | 2003-07-17 | 2008-07-23 | Plexxikon Inc | Composes ayant une activite sur des ppar |
AU2004259738B2 (en) * | 2003-07-17 | 2011-11-17 | Plexxikon, Inc. | PPAR active compounds |
US7531568B2 (en) | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
US8053463B2 (en) | 2007-03-08 | 2011-11-08 | Plexxikon Inc. | PPAR active compounds |
US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
US12060346B2 (en) | 2018-12-17 | 2024-08-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
US11801234B2 (en) | 2020-03-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis |
WO2021252849A1 (fr) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'apol1 et leur utilisation |
US11866446B2 (en) | 2020-08-26 | 2024-01-09 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
CN1391556A (zh) | 2003-01-15 |
KR20020050280A (ko) | 2002-06-26 |
US6605633B1 (en) | 2003-08-12 |
IL149838A0 (en) | 2002-11-10 |
SK6892002A3 (en) | 2002-10-08 |
FR2801585A1 (fr) | 2001-06-01 |
WO2001038305A3 (fr) | 2002-01-24 |
NZ519126A (en) | 2006-03-31 |
ATE263150T1 (de) | 2004-04-15 |
HUP0203603A2 (hu) | 2003-02-28 |
NO20022460D0 (no) | 2002-05-24 |
EP1232144B1 (fr) | 2004-03-31 |
HUP0203603A3 (en) | 2004-03-01 |
CZ20021810A3 (cs) | 2002-08-14 |
PL355724A1 (en) | 2004-05-17 |
EP1232144A2 (fr) | 2002-08-21 |
AU2177601A (en) | 2001-06-04 |
DE60009544T2 (de) | 2004-12-30 |
ES2218266T3 (es) | 2004-11-16 |
DE60009544D1 (de) | 2004-05-06 |
RU2002113771A (ru) | 2004-01-10 |
CA2392225A1 (fr) | 2001-05-31 |
JP2003514894A (ja) | 2003-04-22 |
NO20022460L (no) | 2002-05-24 |
MXPA02005232A (es) | 2002-11-07 |
BR0015695A (pt) | 2002-07-23 |
FR2801585B1 (fr) | 2002-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI295925B (en) | Substituted acylhydroxamic acids and method of reducing tnf-alpha levels | |
FR2824827A1 (fr) | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 | |
KR100378884B1 (ko) | [a]-어닐레이트된피롤유도체와이들의약리학적용도 | |
CA2203618C (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
JP5289046B2 (ja) | Ep4アンタゴニストとしてのキノリン誘導体 | |
EP1017693A1 (fr) | Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant | |
FR2686878A1 (fr) | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. | |
FR2714378A1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
EP1296976B1 (fr) | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine | |
FR2628108A1 (fr) | Derives de piperazine et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant comme ingredients actifs | |
EP1232144B1 (fr) | Antagonistes des recepteurs de l'il-8 | |
FR2804115A1 (fr) | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant | |
WO2001064668A2 (fr) | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'argine-vasopressine | |
JP2003510320A (ja) | 薬剤活性のあるスルホニルアミノ酸誘導体 | |
EP1390348A1 (fr) | Derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 | |
EP0432209A1 (fr) | Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application. | |
AU606819B2 (en) | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides | |
JP2005500381A (ja) | インポテンス治療用の新規化合物 | |
JPH08505877A (ja) | 抗増殖剤としての縮合複素環式グルタミン酸誘導体 | |
FR2617478A1 (fr) | Nouveaux derives d'aryl-heteroaryl cetones, leur procede de preparation ainsi que leur application a titre de medicament | |
FR2768737A1 (fr) | Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant | |
FR2663930A1 (fr) | Nouveaux derives de pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. | |
FR2710639A1 (fr) | Dérivés d'indane cétoniques, leur procédé d'obtention, leur application thérapeutique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000985320 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027006183 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10130454 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6892002 Country of ref document: SK Ref document number: IN/PCT/2002/00517/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2392225 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 519126 Country of ref document: NZ Ref document number: 008160570 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 149838 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/005232 Country of ref document: MX Ref document number: PV2002-1810 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2001 539861 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21776/01 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002113771 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027006183 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-1810 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000985320 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-1810 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000985320 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020027006183 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 519126 Country of ref document: NZ |